Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315341 · ClinicalTrials.gov registry record · Phase 4
Starting Treatment With Agonist Replacement Therapies (START)
A Phase 4 study of Opiate-Related Disorders, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,269
- Enrollment target
- 9
- Study locations
NCT00315341 is a Phase 4 study of Opiate-Related Disorders that has completed, run by University of California, Los Angeles. The registered enrollment target is 1,269 participants. The trial reports 9 study locations across 6 states.
The verdict
NCT00315341, a Phase 4 study of Opiate-Related Disorders, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,269 participants
- Enrollment target
- 9
- Study locations
Study Summary
The Food and Drug Administration (FDA) has requested a study comparing buprenorphine/naloxone (BUP/NX) and methadone (MET) on indices of hepatic safety.
Conditions Studied
Interventions
- DRUG Methadone
- DRUG Buprenorphine/naloxone
Study Locations (9)
California
- Matrix Institute - Los Angeles
- Bi-Valley Medical Clinic INC. - Sacramento
- BAART; Turk Street Clinic - San Francisco
Connecticut
- Hartford Dispensary - Hartford
- CT Counseling Centers - Waterbury
New York
- Addiction Research & Treatment Corp - Brooklyn
Oregon
- CODA-Research - Portland
Pennsylvania
- NET Steps - Philadelphia
Washington
- Evergreen Treatment Services - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,269 participants |
| Start Date | 2006-04 |
| Est. Completion | 2010-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315341
The ClinicalTrials.gov registry entry for NCT00315341 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opiate-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Methadone is the first listed.
NCT00315341 reports 9 study locations spanning 6 distinct geographic areas - top geographies include California, Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT00315341 about?
NCT00315341 is a clinical study titled "Starting Treatment With Agonist Replacement Therapies (START)". The Food and Drug Administration (FDA) has requested a study comparing buprenorphine/naloxone (BUP/NX) and methadone (MET) on indices of hepatic safety.
What is the current status of trial NCT00315341?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,269 participants. The study started on 2006-04. Estimated completion is 2010-08.
What conditions does trial NCT00315341 study?
This clinical trial studies the following conditions: Opiate-Related Disorders.
What interventions are being tested in trial NCT00315341?
The interventions under investigation include: Methadone (DRUG), Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT00315341?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315341 being conducted?
This trial has 9 study locations across California, Connecticut, New York, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opiate-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.